This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walsh, T. J. Articles by Petraitis, V. Search for Related Content PubMed PubMed Citation Articles by Walsh, T. J. Articles by Petraitis, V.

Detection of Galactomannan Antigenemia in Patients Receiving Piperacillin-Tazobactam and Correlations between In Vitro, In Vivo, and Clinical Properties of the Drug-Antigen Interaction

Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,¹ Surgery Service, Veterinary Resources Program, Office of Research Services, National Institutes of Health, Bethesda,³ SAIC, Frederick, Maryland,⁴ Division of Infectious Diseases, Washington Hospital Center, Washington, D.C.²

Received 7 April 2004/ Returned for modification 21 May 2004/ Accepted 8 June 2004

Recent case reports describe patients receiving piperacillin-tazobactam who were found to have circulating galactomannan detected by the double sandwich enzyme-linked immunosorbent assay (ELISA) system, leading to the false presumption of invasive aspergillosis. Since this property of piperacillin-tazobactam and galactomannan ELISA is not well understood, we investigated the in vitro, in vivo, and clinical properties of this interaction. Among the 12 reconstituted antibiotics representing four classes of antibacterial compounds that are commonly used in immunocompromised patients, piperacillin-tazobactam expressed a distinctively high level of galactomannan antigen in vitro (P = 0.001). After intravenous infusion of piperacillin-tazobactam into rabbits, the serum galactomannan index (GMI) in vivo changed significantly (P = 0.0007) from a preinfusion mean baseline value of 0.27 to a mean GMI of 0.83 by 30 min to slowly decline to a mean GMI of 0.44 24 h later. Repeated administration of piperacillin-tazobactam over 7 days resulted in accumulation of circulating galactomannan to a mean peak GMI of 1.31 and a nadir of 0.53. Further studies revealed that the antigen reached a steady state by the third day of administration of piperacillin-tazobactam. Twenty-six hospitalized patients with no evidence of invasive aspergillosis who were receiving antibiotics and ten healthy blood bank donors were studied for expression of circulating galactomannan. Patients (n = 13) receiving piperacillin-tazobactam had significantly greater mean serum GMI values (0.74 ± 0.14) compared to patients (n = 13) receiving other antibiotics (0.14 ± 0.08) and compared to healthy blood bank donors (0.14 ± 0.06) (P < 0.001). Five (38.5%) of thirteen patients receiving piperacillin-tazobactam had serum GMI values > 0.5 compared to none of thirteen subjects receiving other antibiotics (P = 0.039) and to none of ten healthy blood bank donors (P = 0.046). These data demonstrate that among antibiotics that are commonly used in immunocompromised patients, only piperacillin-tazobactam contains significant amounts of galactomannan antigen in vitro, that in animals receiving piperacillin-tazobactam circulating galactomannan antigen accumulates in vivo to significantly increased and sustained levels, and that some but not all patients receiving this antibiotic will demonstrate circulating galactomannan above the threshold considered positive for invasive aspergillosis by the recently licensed double sandwich ELISA.

This article has been cited by other articles:

• Hage, C. A., Reynolds, J. M., Durkin, M., Wheat, L. J., Knox, K. S. (2007). Plasmalyte as a Cause of False-Positive Results for Aspergillus Galactomannan in Bronchoalveolar Lavage Fluid. J. Clin. Microbiol. 45: 676-677 [Full Text]  
• Marty, F. M., Lowry, C. M., Lempitski, S. J., Kubiak, D. W., Finkelman, M. A., Baden, L. R. (2006). Reactivity of (1->3)-{beta}-D-Glucan Assay with Commonly Used Intravenous Antimicrobials.. Antimicrob. Agents Chemother. 50: 3450-3453 [Abstract] [Full Text]  
• Machetti, M., Majabo, M. J., Furfaro, E., Solari, N., Novelli, A., Cafiero, F., Viscoli, C. (2006). Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis. J Antimicrob Chemother 58: 806-810 [Abstract] [Full Text]  
• Francesconi, A., Kasai, M., Petraitiene, R., Petraitis, V., Kelaher, A. M., Schaufele, R., Hope, W. W., Shea, Y. R., Bacher, J., Walsh, T. J. (2006). Characterization and Comparison of Galactomannan Enzyme Immunoassay and Quantitative Real-Time PCR Assay for Detection of Aspergillus fumigatus in Bronchoalveolar Lavage Fluid from Experimental Invasive Pulmonary Aspergillosis.. J. Clin. Microbiol. 44: 2475-2480 [Abstract] [Full Text]  
• Aubry, A., Porcher, R., Bottero, J., Touratier, S., Leblanc, T., Brethon, B., Rousselot, P., Raffoux, E., Menotti, J., Derouin, F., Ribaud, P., Sulahian, A. (2006). Occurrence and Kinetics of False-Positive Aspergillus Galactomannan Test Results following Treatment with {beta}-Lactam Antibiotics in Patients with Hematological Disorders. J. Clin. Microbiol. 44: 389-394 [Abstract] [Full Text]  
• Millon, L., Piarroux, R., Deconinck, E., Bulabois, C.-E., Grenouillet, F., Rohrlich, P., Costa, J.-M., Bretagne, S. (2005). Use of Real-Time PCR To Process the First Galactomannan-Positive Serum Sample in Diagnosing Invasive Aspergillosis. J. Clin. Microbiol. 43: 5097-5101 [Abstract] [Full Text]  
• Bart-Delabesse, E., Basile, M., Al Jijakli, A., Souville, D., Gay, F., Philippe, B., Bossi, P., Danis, M., Vernant, J.-P., Datry, A. (2005). Detection of Aspergillus Galactomannan Antigenemia To Determine Biological and Clinical Implications of Beta-Lactam Treatments. J. Clin. Microbiol. 43: 5214-5220 [Abstract] [Full Text]  
• Machetti, M., Furfaro, E., Viscoli, C. (2005). Galactomannan in Piperacillin-Tazobactam: How Much and to What Extent?. Antimicrob. Agents Chemother. 49: 3984-3985 [Full Text]  
• Mennink-Kersten, M. A. S. H., Ruegebrink, D., Klont, R. R., Warris, A., Gavini, F., Op den Camp, H. J. M., Verweij, P. E. (2005). Bifidobacterial Lipoglycan as a New Cause for False-Positive Platelia Aspergillus Enzyme-Linked Immunosorbent Assay Reactivity. J. Clin. Microbiol. 43: 3925-3931 [Abstract] [Full Text]  
• El Saleeby, C. M., Allison, K. J., Knapp, K. M., Walsh, T. J., Hayden, R. T. (2005). Discordant Rise in Galactomannan Antigenemia in a Patient with Resolving Aspergillosis, Renal Failure, and Ongoing Hemodialysis. J. Clin. Microbiol. 43: 3560-3563 [Abstract] [Full Text]  
• Metan, G., Durusu*, M., Uzun, O. (2005). False Positivity for Aspergillus Antigenemia with Amoxicillin-Clavulonic Acid. J. Clin. Microbiol. 43: 2548-2549 [Full Text]